Drug Trial Radar · NCT02309385
Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis
Last checked: Nov 19, 2026Latest source record: Apr 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Oct 2014
Primary completion
Mar 3, 2017
Study completion Mar 3, 2017
Sponsor
- Lead sponsor
- Aciont IncAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Eye Institute (NEI)
- First posted
- Dec 5, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy, safety, and tolerability of dexamethasone sodium phosphate Visulex (DSP-Visulex) after repeated-dose administration in patients with acute anterior uveitis.
Conditions
- Non-Infectious Anterior Uveitis
Interventions
8% Dexamethasone Sodium Phosphate - VisulexDrug
15% Dexamethasone Sodium Phosphate - VisulexDrug
Prednisolone Acetate (1%) Eye DropsDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with anterior chamber cell ACC grade of zeroTime frame: Day 15
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts Eye Research and Surgery Institution (MERSI)
Cambridge, Massachusetts
Charlotte Eye, Ear, Nose, and Throat Associates
Charlotte, North Carolina
Bergstrom Eye Research
Fargo, North Dakota
B-Berger and Associates
Austin, Texas
Retina and Uveitis Consultants of Texas
San Antonio, Texas
Moran Eye Center, University of Utah
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.